T-cell costimulation--biology, therapeutic potential, and challenges.

@article{Sharpe2006TcellCT,
  title={T-cell costimulation--biology, therapeutic potential, and challenges.},
  author={Arlene H Sharpe and Abul K Abbas},
  journal={The New England journal of medicine},
  year={2006},
  volume={355 10},
  pages={973-5}
}
n engl j med 10.1056/nejmp068087 is tightly regulated to prevent autoreactivity. The processes of T-cell activation and self-tolerance are therefore potential targets for manipulation by drugs — hence, the recent phase 1 trial of a “superagonistic” monoclonal antiCD28 antibody that was conducted in Britain on behalf of the German firm TeGenero, with unexpected and devastating results that are described in the report by Suntharalingam et al. in this issue of the Journal. T-cell activation… CONTINUE READING